Table 1.
Study Participant Characteristics (N=267)
| Variable | |
|---|---|
| Age | 58 (SD 13) Range 24 – 83 |
| Race | |
| Not white | 70 (26%) |
| White | 197 (74%) |
| Education | |
| High school or less | 38 (14%) |
| More than high school | 227 (86%) |
| Married | |
| No | 116 (44%) |
| Yes | 149 (56%) |
| Body Mass Index (BMI) – mean SD | 30 (SD 7) Range 17 – 65 |
| Underweight (<18.5) | 3 (1%) |
| Normal (18.5 to <25) | 72 (27%) |
| Overweight (25 to <30) | 83 (31%) |
| Obese I (30 or above) | 109 (41%) |
| Menopausal status at breast cancer diagnosis | |
| Pre-menopausal | 81 (31%) |
| Post-menopausal | 183 (69%) |
| Breast cancer stage | |
| I | 67 (25%) |
| II | 133 (50%) |
| III | 67 (25%) |
| Breast cancer phenotype | |
| HR negative/HER-2 negative | 78 (29%) |
| HR negative/HER-2 positive | 34 (13%) |
| HR positive/HER-2 negative | 120 (45%) |
| HR positive/HER-2 positive | 34 (13%) |
| Breast cancer surgery | |
| None | 7 (3%) |
| Lumpectomy | 126 (48%) |
| Mastectomy | 127 (49%) |
| Anti-HER-2 therapy | 67 (25%) |
| Chemotherapy timing | |
| Neoadjuvant | 103 (39%) |
| Adjuvant | 159 (60%) |
| Both | 1 (1%) |
| Chemotherapy regimens -- drug combinations | |
| AC-T (doxorubicin/cyclophosphamide followed or preceded by paclitaxel/Taxol) | 82 (31%) |
| AC-TC (doxorubicin/cyclophosphamide plus paclitaxel/carboplatin) | 19 (7%) |
| TC (docetaxel/cyclophosphamide; N=3 plus anti-HER-2 therapy) | 70 (27%) |
| TCH (docetaxel/carboplatin plus anti-HER-2 therapy) | 41 (16%) |
| Other | 51 (19%) |
HR=hormone receptor. HER-2: Human Epithelial Growth Factor receptor 2.